1292290-38-0

Basic information

• Product Name: (3S)-3-(4-{[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxy}phenyl)hex-4-ynoic acid
• Synonyms: (3S)-3-(4-{[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxy}phenyl)hex-4-ynoic acid
• CAS NO: 1292290-38-0
• Molecular Weight: 491.63
• Mol File: 1292290-38-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (3S)-3-(4-{[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxy}phenyl)hex-4-ynoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-3-(4-{[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxy}phenyl)hex-4-ynoic acid(1292290-38-0)
• EPA Substance Registry System: (3S)-3-(4-{[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxy}phenyl)hex-4-ynoic acid(1292290-38-0)

Safety Data

• Hazardous Substances Data: 1292290-38-0(Hazardous Substances Data)

Usage

General Description

The chemical "(3S)-3-(4-{[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxy}phenyl)hex-4-ynoic acid" is a complex compound with a long systematic name. It is a synthetic derivative of hex-4-ynoic acid, containing a unique arrangement of functional groups including benzyl, spiro[indene-1,4′-piperidine], and phenyl groups. (3S)-3-(4-{[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxy}phenyl)hex-4-ynoic acid may have potential applications in medicinal chemistry and drug development due to its unique structure and potential biological activity. However, further research and study are needed to fully understand its properties and potential applications.

Upstream product

• 137730-67-7 spiro(1H-indene-1,4'-piperidine) hydrochloride 
• 1292291-39-4 ethyl (S)-3-(4-((4-(spiro[indene-1,4'-piperidin]-1'-ylmethyl)benzyl)oxy)phenyl)hex-4-ynoate 
• 1292291-10-1 (4-(spiro[indene-1,4'-piperidin]-1'-ylmethyl)phenyl)methanol 
• 865233-35-8 (3S)-3-(4-hydroxy-phenyl)-hex-4-ynoic acid 
• 865233-33-6 (+/-)-5-[1-(4-hydroxy-phenyl)-but-2-ynyl]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 865233-34-7 4-hydroxy-β-1-propyn-1-ylbenzenepropanoic acid 
• 17474-27-0 5-(4-hydroxy-benzylidene)-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 71831-21-5 4-(bromomethyl)benzyl alcohol 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 123-08-0 4-hydroxy-benzaldehyde 

Relevant articles and documents

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)

The G protein-coupled receptor 40 (GPR40) also known as free fatty acid receptor 1 (FFAR1) is highly expressed in pancreatic, islet β-cells and responds to endogenous fatty acids, resulting in amplification of insulin secretion only in the presence of elevated glucose levels. Hypothesis driven structural modifications to endogenous FFAs, focused on breaking planarity and reducing lipophilicity, led to the identification of spiropiperidine and tetrahydroquinoline acid derivatives as GPR40 agonists with unique pharmacology, selectivity, and pharmacokinetic properties. Compounds 1 (LY2881835), 2 (LY2922083), and 3 (LY2922470) demonstrated potent, efficacious, and durable dose-dependent reductions in glucose levels along with significant increases in insulin and GLP-1 secretion during preclinical testing. A clinical study with 3 administered to subjects with T2DM provided proof of concept of 3 as a potential glucose-lowering therapy. This manuscript summarizes the scientific rationale, medicinal chemistry, preclinical, and early development data of this new class of GPR40 agonists.